Ono Pharmaceutical (OTCMKTS:OPHLF) Rating Increased to Strong-Buy at Zacks Research

Ono Pharmaceutical (OTCMKTS:OPHLF) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Ono Pharmaceutical Trading Up 4.4%

Shares of OTCMKTS:OPHLF opened at $15.56 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56. Ono Pharmaceutical has a 1 year low of $10.06 and a 1 year high of $18.67. The company has a market cap of $7.31 billion, a P/E ratio of 15.72 and a beta of 0.34. The stock’s fifty day moving average price is $14.40 and its 200-day moving average price is $14.67.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.